Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05975554
Other study ID # A096090
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 26, 2023
Est. completion date September 1, 2025

Study information

Verified date November 2023
Source Cambridge University Hospitals NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trail is to compare the differences in carotid plaque Treg cells' gene signature for activation, proliferation, and suppressive function using scRNA-seq in patients treated with IL-2 compared to control.


Description:

Up till now our Lab has looked at Tregs and immune cells in the blood. The question remains whether low dose IL-2 can have the desired effect on Tregs in atherosclerotic plaques where they could alter the pathophysiology and potentially clinical outcomes for patients. Up until recently, the cellular composition and cell-specific expression patterns of human atherosclerotic plaques remained elusive. However, recent breakthroughs studies using scRNA-seq, CITE-seq, and single-cell ATAC-seq on human carotid plaques have offered important insight into plaque composition, cell heterogeneity, and cell-cell interactions giving new perspectives on mechanisms of disease. The next logical stage is to use this new insight and powerful biological tool to assist in drug development for patients. Therefore, the aims of the study are: 1. To assess if low dose IL-2, given systemically to patients at our proposed dose, can alter Tregs in atherosclerotic plaques (the disease tissue) to exhibit a proliferating, activated, and immunosuppressive phenotype 2. To assess if modulating plaque Tregs can cause a shift in the plaque immune landscape to a less inflammatory phenotype 3. To study the relationship between plaque and circulating immune cells after systemic immune modulation


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date September 1, 2025
Est. primary completion date August 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Presence of carotid stenosis on either ultrasound or CT scan. - Planned to undergo carotid endarterectomy. Exclusion Criteria: - Autoimmune disease - Any regular immunosuppressive treatment [Inhaled or topical steroids are permissible] - Modified Rankin Scale score of =4 at screening - Known active hepatic disease or alanine aminotransferase (ALT) > 2xULN - Severe chronic kidney disease (defined as eGFR < 30 ml/min/1.73m2) - Allergy or intolerance to aldesleukin - Signs or symptoms of active infection - History of human immunodeficiency virus (HIV), hepatitis B or C - Current malignancy requiring active treatment - Vaccine within 4 weeks prior to screening or plans for vaccination during study period - Women of child-bearing potential and pregnancy - Women who are breast-feeding - Clinically relevant medical or surgical conditions that, in the opinion of the

Study Design


Intervention

Drug:
Interleukin-2 [IL-2]
5 sequential days of treatment (1.5MIU/day subcutaneously)
Procedure:
Standard care - Carotid Endarterectomy
Standard care for patients with carotid stenosis undergoing carotid endarterectomy

Locations

Country Name City State
United Kingdom Addenbrookes Hospital Cambridge Cambridgeshire

Sponsors (1)

Lead Sponsor Collaborator
Cambridge University Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Other immune cell and vascular smooth muscle cell gene expression As per primary outcome measure but in immune cells and vascular smooth muscle cells (excluding Treg & Teff cells). Differential gene expression will be assessed using standard techniques (Z-Score) Time of surgery
Other Ligand-receptor interactions. Differential regulation of ligand-receptor interactions between control and IL-2 treated cells will be identified by comparing single-cell/single-cell ligand-receptor interaction scores for the two groups. This measure is descriptive in nature. Time of surgery
Other T-Cell receptor profile Difference in TCR clonality in plaques between the two groups will be assessed from clonotypes based on identical V-J gene usage and identical CDR3 junctions. Time of surgery
Other Inflammatory pathway activation. Activation of inflammatory pathways both at plaque and systemic level. Assess for enrichment of genes involved in inflammatory pathways - enrichment score. Time of surgery
Primary Difference in gene expression in Tregs Comparing differential gene expression using scRNA-seq technologies, from isolated Tregs from carotid plaques from the two patient groups (IL-2 treatment and control). Differential gene expression will be assessed using standard techniques (Z-Score) Time of surgery
Secondary Difference in gene expression in Teff cells. Comparing differential gene expression using scRNA-seq technologies, from isolated Teffs from carotid plaques from the two patient groups (IL-2 treatment and control). Differential gene expression will be assessed using standard techniques (Z-Score) Time of surgery
Secondary Immune cell gene signature, in plaque and blood. Difference in immune cell gene signature will be compared using scRNA-seq in both plaque and blood samples, and further compared between IL-2 and control groups. Comparative analysis will be completed using gene set enrichment analysis (Enrichment Score). Time of surgery
Secondary Difference in gene expression patterns in Treg & Teff cells. Comparison between Treg and Teff cells collected at baseline and day of surgery will be compared between IL-2 and control groups. Differential gene expression will be assessed using standard techniques (Z-Score) Baseline and at time of surgery
See also
  Status Clinical Trial Phase
Completed NCT03248401 - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Phase 4
Withdrawn NCT03630835 - 99m Tc-ANNexin-V-128 Scintigraphy for the Identification of Complicated Carotid Atherosclerotic Plaques Phase 2/Phase 3
Completed NCT02722720 - Carotid Arteries Stenting Complications: Transradial Approach Versus Transfemoral N/A
Completed NCT01893489 - Visualization of Carotid Atherosclerosis by 68Ga-MSA Phase 1
Withdrawn NCT00861159 - RLIP76 in Human Serum in Adults With Rheumatologic Diseases N/A
Recruiting NCT01743404 - Study of Anti-atherosclerotic Activity of Inflaminat in Asymptomatic Participants With Subclinical Atherosclerosis Phase 2
Completed NCT00636766 - Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque N/A
Recruiting NCT06166121 - Study on Hyperlipidemia Combined With Carotid Atherosclerosis With ShenJu Granules N/A
Withdrawn NCT03382249 - Sonodynamic Therapy Manipulates Atherosclerosis Regression Trial on Patients With Carotid Atherosclerotic Plaques Phase 1/Phase 2
Recruiting NCT04679727 - The Carotid Artery Multi-modality Imaging Prognostic (CAMP) Study
Withdrawn NCT02995642 - Targeted PET/CT and PET/MRI Imaging of Vascular Inflammation Phase 2
Suspended NCT01000181 - Imaging 61CuATSM Uptake in Atherosclerotic Plaque Using PET-CT N/A
Completed NCT00001368 - Potential Risk Factors for Stroke Phase 1
Recruiting NCT04537403 - PET Detection of CCR2 in Human Atherosclerosis Phase 1
Recruiting NCT05800821 - Prediction of Cerebral Hyperperfusion Syndrome After Carotid Revascularization Using Deep Learning
Completed NCT00147251 - Stop Atherosclerosis in Native Diabetics Study Phase 4
Completed NCT00147797 - Influence of Pravastatin on Carotid Artery Structure and Function in HIV-infected Patients Under Antiretroviral Therapy N/A
Completed NCT00180518 - ACCULINK for Revascularization of Carotids in High Risk Patients "The ARCHeR Trial" Phase 2/Phase 3
Completed NCT05230576 - Intelligent Detection of Carotid Plaque and Its Stability Based on Deep Learning Dynamic Ultrasound Scanning
Terminated NCT03764306 - New Ischemic Cerebral Lesions After Endarterectomy vs. Stenting for the Treatment of Symptomatic Carotid Stenosis N/A